Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: Invest2Ride who wrote (447)	9/26/1998 1:43:00 AM
From: James Perry	Read Replies (1) \| Respond to of 1025

The presentation made at Emerald Research was made with numbers which Boehringer Mannheim reported in making royalty payments. A suit is pending because Igen does not agree with the numbers reported by Boehringer (BMG). Igen claims that the sales numbers (and royalties due or paid) are much higher than those shown in the slide show - that more than 6000 sales had been made months ago. I believe that Igen is correct in her claims (as witness the fact that she recently was granted a pre-trial injunction to prevent BMG from selling machines outside the area covered by her license). However, I also understand that if Igen suggested any number greater than actually proved at trial, she would be subject to suit by stockholders for fraudulently reporting inflated values - and there are law firms specializing in bringing such suits. So she is following the proper and conservative course in using the numbers reported by BMG, even though it results in understatements in both her published financial reports and in that display.